company background image
OCUP

Ocuphire PharmaNasdaqCM:OCUP Stock Report

Market Cap

US$75.3m

7D

19.5%

1Y

-33.9%

Updated

26 Nov, 2021

Data

Company Financials +
OCUP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

OCUP Stock Overview

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders.

Price History & Performance

Summary of all time highs, changes and price drops for Ocuphire Pharma
Historical stock prices
Current Share PriceUS$4.35
52 Week HighUS$13.81
52 Week LowUS$3.35
Beta0
1 Month Change9.02%
3 Month Change-4.61%
1 Year Change-33.89%
3 Year Changen/a
5 Year Changen/a
Change since IPO-27.50%

Recent News & Updates

Oct 08
Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation

Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Aug 05

Ocuphire Pharma: An Undervalued Ophthalmic Play

Ocuphire is positioning itself as a leading ophthalmic player, providing novel therapeutic solutions for both front and back of the eye indications. The company recently announced positive topline results for its lead candidate, Nyxol, in a Phase 3 study for Reversal of Mydriasis (RM) and in a Phase 2 study for Presbyopia. The company is targeting multi-billion dollar market opportunities in four indications, which remain largely unmet, and in some cases with no approved therapies or competition.

Shareholder Returns

OCUPUS PharmaceuticalsUS Market
7D19.5%-0.5%-2.7%
1Y-33.9%17.7%21.3%

Return vs Industry: OCUP underperformed the US Pharmaceuticals industry which returned 17.7% over the past year.

Return vs Market: OCUP underperformed the US Market which returned 21.3% over the past year.

Price Volatility

Is OCUP's price volatile compared to industry and market?
OCUP volatility
OCUP Average Weekly Movement10.0%
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement5.9%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.2%

Stable Share Price: OCUP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: OCUP's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a5Mina Soochhttps://www.ocuphire.com

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330.

Ocuphire Pharma Fundamentals Summary

How do Ocuphire Pharma's earnings and revenue compare to its market cap?
OCUP fundamental statistics
Market CapUS$75.26m
Earnings (TTM)-US$69.06m
Revenue (TTM)US$589.00k

127.8x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OCUP income statement (TTM)
RevenueUS$589.00k
Cost of RevenueUS$8.06m
Gross Profit-US$7.47m
ExpensesUS$61.59m
Earnings-US$69.06m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-3.99
Gross Margin-1,268.76%
Net Profit Margin-11,724.96%
Debt/Equity Ratio0.0%

How did OCUP perform over the long term?

See historical performance and comparison

Valuation

Is Ocuphire Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OCUP ($4.35) is trading below our estimate of fair value ($407.83)

Significantly Below Fair Value: OCUP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OCUP is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: OCUP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OCUP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OCUP is overvalued based on its PB Ratio (3.7x) compared to the US Pharmaceuticals industry average (2.7x).


Future Growth

How is Ocuphire Pharma forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

69.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OCUP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OCUP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OCUP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OCUP's revenue (84.4% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: OCUP's revenue (84.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OCUP's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Ocuphire Pharma performed over the past 5 years?

-733.8%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: OCUP is currently unprofitable.

Growing Profit Margin: OCUP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if OCUP's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare OCUP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OCUP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: OCUP has a negative Return on Equity (-335.8%), as it is currently unprofitable.


Financial Health

How is Ocuphire Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: OCUP's short term assets ($23.2M) exceed its short term liabilities ($2.6M).

Long Term Liabilities: OCUP has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: OCUP is debt free.

Reducing Debt: OCUP had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OCUP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: OCUP has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 86% each year.


Dividend

What is Ocuphire Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OCUP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OCUP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OCUP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OCUP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OCUP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Mina Sooch (53 yo)

3.75yrs

Tenure

US$483,073

Compensation

Ms. Mina Patel Sooch, MBA serves as Founder and Chief Executive Officer of Ocuphire Pharma, Inc. since October 2018 and serves as its President and Treasurer and serves as its Vice Chair of the Board since...


CEO Compensation Analysis

Compensation vs Market: Mina's total compensation ($USD483.07K) is about average for companies of similar size in the US market ($USD553.25K).

Compensation vs Earnings: Mina's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: OCUP's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: OCUP's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: OCUP insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 59.6%.


Top Shareholders

Company Information

Ocuphire Pharma, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Ocuphire Pharma, Inc.
  • Ticker: OCUP
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$75.257m
  • Shares outstanding: 17.30m
  • Website: https://www.ocuphire.com

Number of Employees


Location

  • Ocuphire Pharma, Inc.
  • 37000 Grand River Avenue
  • Suite 120
  • Farmington Hills
  • Michigan
  • 48335
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/26 23:17
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.